Antileprosy Drugs: WHO Multidrug Therapy, Mechanisms and Monitoring

Medical education review; updated 10 November 2026. Regimens must be individualized and checked against local guidelines.

Overview

Leprosy (Hansen disease) is a chronic infection caused by Mycobacterium leprae and, less commonly, M. lepromatosis, affecting skin and peripheral nerves. Early diagnosis, multidrug therapy (MDT), nerve assessment and management of inflammatory reactions prevent disability [1].

Classification and WHO treatment

WHO recommends the same three agents—rifampicin, dapsone and clofazimine—for both paucibacillary (PB) and multibacillary (MB) disease, for 6 months in PB and 12 months in MB [1]. This replaces obsolete two-drug PB recommendations. Adult WHO blister-pack regimens commonly use rifampicin 600 mg once monthly, clofazimine 300 mg once monthly plus 50 mg daily, and dapsone 100 mg daily; children require age/weight-appropriate regimens. Programmatic implementation and interruptions should be managed by a leprosy service [1].

Mechanisms

  • Rifampicin: inhibits the beta subunit of bacterial DNA-dependent RNA polymerase; potent bactericidal activity against M. leprae.
  • Dapsone: a sulfone inhibiting bacterial dihydropteroate synthase and folate synthesis; mainly bacteriostatic.
  • Clofazimine: a lipophilic riminophenazine with antimycobacterial and anti-inflammatory effects; likely involves membrane/redox effects, and its long tissue retention contributes to delayed clearance.

Adverse effects and pharmacokinetics

Rifampicin induces several drug-metabolizing enzymes and transporters, compromising selected hormonal contraceptives, anticoagulants and antiretrovirals; reddish-orange bodily fluid discoloration is expected. Dapsone may cause hemolysis, methemoglobinemia, agranulocytosis and potentially serious hypersensitivity; check blood count and G6PD status as appropriate, noting hemolysis can occur without G6PD deficiency. Clofazimine causes reddish-brown skin discoloration, dryness and gastrointestinal intolerance, sometimes severe with prolonged use. Pregnancy and breastfeeding decisions require specialist guidance, not outdated FDA letter categories.

Reactional states and nerve care

Type 1 reversal reactions and type 2 erythema nodosum leprosum are immune-inflammatory complications and do not by themselves indicate antimicrobial failure. Urgent assessment of new nerve pain, sensory loss or weakness is necessary; corticosteroids and selected immunomodulatory treatments may be used under specialist care. MDT must not be stopped solely because a reaction occurs [1].

Public health and prevention

Contact evaluation, stigma-free care and disability-prevention measures are essential. WHO advises eligible contacts may receive single-dose rifampicin postexposure prophylaxis only after screening and exclusion of leprosy/TB and relevant contraindications [1].

Key correction

The previously stated dapsone 200 mg daily adult dose and two-drug regimen for PB leprosy were incorrect; this version uses WHO’s three-drug standard [1].

References

  1. World Health Organization. Leprosy. WHO fact sheet. Accessed 2026 Nov 10. Available from: https://www.who.int/news-room/fact-sheets/detail/leprosy
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *